Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell–like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Nowakowski, Grzegorz S., Hong, Fangxin, Scott, David W., Macon, William R., King, Rebecca L., Habermann, Thomas M., Wagner-Johnston, Nina, Casulo, Carla, Wade, James L., Nagargoje, Gauri G., Reynolds, C. M., Cohen, Jonathon B., Khan, Nadia, Amengual, Jennifer E., Richards, Kristy L., Little, R. F., Leonard, John P., Friedberg, Jonathan W., Kostakoglu, Lale, Kahl, Brad S., Witzig, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078264/
https://ncbi.nlm.nih.gov/pubmed/33555941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01375
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados